Hoth Therapeutics files patent for weight loss therapeutic and side effect mitigation

Hoth Therapeutics, Inc.

Filed a patent application with USPTO on January 8, 2024 for a therapeutic targeting obesity and side effects of weight loss drugs.
Application aims to mitigate adverse effects associated with GLP-1 agonists, anticonvulsants, opioid antagonists, and NRIs.
No details disclosed on the specific compound, mechanism, or development stage.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.